The Role of Chemotherapy in the Treatment of Head and Neck Carcinoma
Authors:
J. Klozar
Authors place of work:
Katedra otorinolaryngologie IPVZ, Praha
přednosta prof. MUDr. J. Betka, DrSc.
; Klinika otorinolaryngologie a chirurgie hlavy a krku 1. LF UK a FN Motol, Praha
Published in the journal:
Otorinolaryngol Foniatr, 57, 2008, No. 3, pp. 159-164.
Category:
Comprehensive Reports
Summary
The paper presents an overview of the use of chemotherapy in the treatment of squamous cell carcinoma of head and neck. The progress in irradiation techniques and novel drugs together with the fact that a growing part of patients refuses radical surgery leads to increasing fraction of head and neck tumours treated non surgically. Even when this development probably causes a decreased survival, it goes through in many countries. There is evidence in the present that concurrently administered chemotherapy and radiotherapy yields better results than radiotherapy alone. There is no such evidence in neoadjuvant chemotherapy, but with novel drugs its importance can be proved in the future. Adjuvant chemotherapy does not improve treatment results in head and neck cancer. Biological treatment is a very hopeful method especially in the combination with radiotherapy. The results of concurrent administration of EGFR (epidermal growth factor receptor) inhibitors and radiotherapy are probably better than currently used chemoradiation with platinum drugs while having substantially lower toxicity.
Key words:
chemotherapy, squamous cell carcinoma, irradiation techniques, radiotherapy, biological treatment.
Zdroje
1. Induction chemotherapy plus radiation compared with surgery plus radiation in patiens with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N. Engl. J. Med., 324, 1991, s. 1685-1690.
2. Adelstein, D. J., Li, Y., Adams, G. L., Wagner, H., Jr., Kish, J. A., Ensley, J.F., Schiller, D. E., Forastiere, A. A.: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol., 21, 2003, s. 92-98.
3. al-Sarraf, M., Hussain, M.: Head and neck cancer: present status and future prospects of adjuvant chemotherapy. Cancer Invest, 13, 1995, s. 41-53.
4. Ang, K. K., Berky, B. A., Tu, X., Zhang, H. Z., Katz, R., Hammond, E. H., Fu, K. K., Milas, L.: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res., 62, 2002, s. 7350-7356.
5. Benzen, S. M., Trotli, A.: Evaluation of early and late toxicities in chemoradiation trials. J. Clin. Oncol., 25, 2007, s. 4096-4103.
6. Bernier, J., Domenge, C., Ozsahin, M., Matuszewska, K., Lefebvre, J. L., Greiner, R. H., Goraly, J., Maingon, P., Rolland, F., Bolla, M. et al.: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med., 350, 2004, s. 1945-1952.
7. Bernier, J., Schneider, D.: Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck? Eur J. Cancor, 43, 2007, s. 35-45.
8. Bernier, J.: Alteration of radiotherapy fractionation and concurrent chemotherapy: a new frontier in head and neck oncology? Nat. Clin. Pract. Oncol., 2, 2005, s. 305-314.
9. Bonner, J. A., Harari, P. M., Goraly, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J. et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med., 354, 2006, s. 567-578.
10. Cooper, J. S., Pajak, T. F., Forastiere, A. A., Jacobs, J., Campbell, B. H., Axman, S. B., Kish, J. A., Kim, H. E., Cmelak, A. J., Rotman, M. et al.: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med., 350, 2004, s. 1937-1944.
11. Curran, D., Goraly, J., Harari, P. M., Ang, K. K., Cohen, R. B., Kies, M. S., Jassem, J., Baselga, J., Rowinsky, E. K., Amellal, N. et al.: Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J. Clin. Oncol., 25, 2007, s. 2191-2197.
12. Denis, F., Garaud, P., Bardet, E., Alfonsi, M., Sire, C., Germain, T., Bergerot, P., Thein, B., Tortochaux, J., Oudinot, P. et al.: Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int. J. Radiat. Oncol. Biol. Phys., 55, 2003, s. 93-98.
13. Domenge, C., Hill, C., Lefebvre, J. L., De Raucourt, D., Thein, B., Wibault, P., Marandas, P., Coche-Dequeant, B., Stromboni-Luboinski, M., Sancho-Garnier, H. et al.: Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d’Etude des Tumeurs de la Tete et du Cou (GETTEC). Br. J. Cancor, 83, 2000, s. 1594-1598.
14. Forastiere, A. A., Goepfert, H., Maor, M., Pajak, T. F., Weber, R., Kortison, W., Glisson, B., Trotli, A., Ridge, J. A., Chao, C. et al.: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Engl. J. Med., 349, 2003, s. 2091-2098.
15. Hitt, R., Lopez-Pousa, A., Martinez-Trufero, J., Escrig, V., Charles, J., Rizo, A., Isla, D., Vega, M. E., Marti, J. L., Lobo, F. et al.: Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J. Clin. Oncol., 23, 2005, s. 8636-8645.
16. Hoffman, H. T., Porter, K., Karneol, L. H., Cooper, J. S., Weber, R. S., Langer, C. J, Ang, K. K., Gay, G., Stewart, A., Robinson, R. A.: Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoskope, 116, 2006, s. 1-13.
17. Huguenin, P., Beer, K. T., Allal, A., Rufibach, K., Friedli, C., Davis, J. B., Pestalozzi, B., Schmidt, S., Thoni, A., Ozsahin, M. et al.: Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J. Clin. Oncol., 22, 2004, s. 4665-4673.
18. Janot F., Rhein B., Koka V. N., Wibault P., Domenge C., Bessede J. P., Marandas P., Schwaab G., Luboinski B.: Laryngeal preservation with induction chemotherapy. Experience of two GETTEC centers, between 1985 and 1995. Ann. Otolaryngol Chir. Cervicofac., 119, 2002, s. 12-20.
19. Lee, K. C., Lee, S. H., Lee, Y., Park, S. H., Park, J., Cho, E. K., Shin, D. B., Lee, J. H., Kim, D. Y., Kim, S. T.: Prospective pilot study of consolidation chemotherapy with Docetaxel and Cisplatin After Concurrent Chemoradiotherapy for Advanced Head and Neck cancer. Int. J. Radiat. Oncol. Biol. Phys., Nov. 7: [Epub ahead of print] 2007.
20. Lefebvre, J. L., Chevalier, D., Luboinski, B., Kirkpatrick, A., Collette, L., Sahmoud, T.: Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J. Natl. Cancor, 88, 1996, s. 890-899.
21. Liang, K., Ang, K. K., Milas, L., Hunter, N., Fan, Z.: The epidermal growth factor receptor mediates radioresistance. Int. J. Radiat. Oncol. Biol. Phys., 57, 2003, s. 246-254.
22. Magne, N., Pivot, X., Bensadoun, R. J., Guardiola, E., Poissonnet, G., Dassonville, O., Francouzů, M., Formento, J. L., Demard, F., Schneider, M. et al.: The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy. Eur. J. Cancor, 37, 2001, s. 2169-2177.
23. Mechl, Z., Abrahamova, J.: Postavení cetuximabu v léčbě pokročilých nádorů ORL oblasti. Remedia, 16, 2006, s. 110-115.
24. Lignin, J. P., Bourhis, J., Domenge, C., Designe, L.: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet, 355, 2000, s. 949-955.
25. Lignin, J. P., le Maitre, A., Bourhis, J.: Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int. J. Radiat. Oncol. Biol. Phys., 69, 2007, s. 112-114.
26. Vermorken, J., Mesia, R., Vega, V., Remenar, E., Hitt, R., Kawecki, A., Rottey, S., Amellal, N., Cupissol, D., Licitra, L.: Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy: Results of a randomized phase III (Extreme) study. In ASCO 2007 (Abstract No 6091; updated information presented).
27. Vermorken, J. B., Remenar, E., van Herpen, C., Gorila, T., Mesia, R., Degardin, M., Stewart, J. S., Jelic, S., Betka, J., Preiss, J. H. et al.: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N. Engl. J. Med., 357, 2007, s. 1695-1704.
28. Vermorken, J. B.: Medical treatment in head and neck cancer. Ann. Oncol., 16, 2005, s. 258-264.
29. Senft, T. G., Grabenbauer, G. G., Rodel, C. M., Thiel, H. J., Aydin, H., Rohloff, R., Wustrow, T. P., Iro, H., Popella, C., Schalhorn, A.: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J. Clin. Oncol., 16, 1998, s. 1318-1324.
30. Zorat, P. L., Paccagnella, A., Cavaniglia, G., Loreggian, L., Gava, A., Mione, C. A., Boldrin, F., Marchiori, C., Lunghi, F., Fede, A. et al.: Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J. Natl. Cancer Indy., 96, s. 1714-1717.
Štítky
Audiology Paediatric ENT ENT (Otorhinolaryngology)Článok vyšiel v časopise
Otorhinolaryngology and Phoniatrics
2008 Číslo 3
Najčítanejšie v tomto čísle
- Extraesophageal Reflux (Part 2) ORL Manifestation and Therapy
- Middle Ear Inflammation on the Basis of Chronic Purulent Middle Ear Inflammation with Cholesteatoma
- Extraesophageal Reflux (Part 1) Epidemiology, Pathophysiology and Diagnostics
- Auditory Neuropathy